Promising Glioma Results

Forma Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced recently that the company’s investigational IDH1m inhibitor, olutasidenib, demonstrated a preliminary disease control rate of 50% in heavily pre-treated patients with predominantly enhancing, recurrent mIDH1 glioma. These data indicate that olutasidenib is well-tolerated and may provide clinical benefit in patients with recurrent glioma, a patient population with very limited treatment options. For results of the Best Response per RANO and the Blinded Independent Central Review (BICR) using Volumetric Assessment as conducted by Imaging Endpoints, view presentation.